Cargando…

Combining clinical and MRI data to manage PI-RADS 3 lesions and reduce excessive biopsy

BACKGROUND: Prostate Imaging Reporting and Data System version 2 (PI-RADS V2) 3 category lesions are of intermediate status with an equivocal risk of presenting clinically significant prostate cancer (csPCa). How to avoid excessive biopsies while improving the csPCa detection rate in these lesions h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Shuo, Zhao, Wenlu, Tan, Shuangxiu, Zhang, Yueyue, Wei, Chaogang, Chen, Tong, Shen, Junkang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354292/ https://www.ncbi.nlm.nih.gov/pubmed/32676408 http://dx.doi.org/10.21037/tau-19-755

Ejemplares similares

MRI Based Radiomics Compared With the PI-RADS V2.1 in the Prediction of Clinically Significant Prostate Cancer: Biparametric vs Multiparametric MRI
por: Chen, Tong, et al.
Publicado: (2022)

Prostate Cancer Differentiation and Aggressiveness: Assessment With a Radiomic‐Based Model vs. PI‐RADS v2
por: Chen, Tong, et al.
Publicado: (2018)

A PI-RADS-Based New Nomogram for Predicting Clinically Significant Prostate Cancer: A Cohort Study
por: Zhang, Yueyue, et al.
Publicado: (2020)

A nomogram based on PI-RADS v2.1 and clinical indicators for predicting clinically significant prostate cancer in the transition zone
por: Wei, Chaogang, et al.
Publicado: (2021)

Improving the understanding of PI-RADS in practice: characters of PI-RADS 4 and 5 lesions with negative biopsy
por: Wang, Yu-Hao, et al.
Publicado: (2023)

Comparison of PSA density and lesion volume strategies for selecting men with equivocal PI-RADS 3 lesions on bpMRI for biopsies
por: Kortenbach, Karen-Cecilie, et al.
Publicado: (2022)

Can a prostate biopsy be safely deferred on PI-RADS 1,2 or 3 lesions seen on pre-biopsy mp-MRI?
por: Abdul Raheem, Rickaz, et al.
Publicado: (2022)

Follow-up of men with a PI-RADS 4/5 lesion after negative MRI/Ultrasound fusion biopsy
por: Kornienko, Kira, et al.
Publicado: (2022)

Perilesional Targeted Biopsy Combined with MRI-TRUS Image Fusion-Guided Targeted Prostate Biopsy: An Analysis According to PI-RADS Scores
por: Tomioka, Masayuki, et al.
Publicado: (2023)

Equivocal PI-RADS Three Lesions on Prostate Magnetic Resonance Imaging: Risk Stratification Strategies to Avoid MRI-Targeted Biopsies
por: Osses, Daniël F., et al.
Publicado: (2020)

Serum miRNAs Support the Indication for MRI-Ultrasound Fusion-Guided Biopsy of the Prostate in Patients with Low-PI-RADS Lesions
por: Keck, Bastian, et al.
Publicado: (2021)

Combination of PI-RADS score and PSAD can improve the diagnostic accuracy of prostate cancer and reduce unnecessary prostate biopsies
por: Wang, Changming, et al.
Publicado: (2022)

Evaluation of a multiparametric MRI radiomic-based approach for stratification of equivocal PI-RADS 3 and upgraded PI-RADS 4 prostatic lesions
por: Brancato, Valentina, et al.
Publicado: (2021)

Machine learning-based radiomics model to predict benign and malignant PI-RADS v2.1 category 3 lesions: a retrospective multi-center study
por: Jin, Pengfei, et al.
Publicado: (2023)

Does Adding Standard Systematic Biopsy to Targeted Prostate Biopsy in PI-RADS 3 to 5 Lesions Enhance the Detection of Clinically Significant Prostate Cancer? Should All Patients with PI-RADS 3 Undergo Targeted Biopsy?
por: Gomez-Gomez, Enrique, et al.
Publicado: (2021)

New Biopsy Techniques and Imaging Features of Transrectal Ultrasound for Targeting PI-RADS 4 and 5 Lesions
por: Park, Byung Kwan, et al.
Publicado: (2020)

Impact of PI-RADS v2 on indication of prostate biopsy
por: Rozas, George de Queiroz, et al.
Publicado: (2019)

CRISPR/Cas9 targeting of the androgen receptor suppresses the growth of LNCaP human prostate cancer cells
por: Wei, Chaogang, et al.
Publicado: (2018)

The Application of Biopsy Density in Transperineal Templated-Guided Biopsy Patients With PI-RADS<3
por: Zhu, Hai, et al.
Publicado: (2022)

MRI in early prostate cancer detection: how to manage indeterminate or equivocal PI-RADS 3 lesions?
por: Schoots, Ivo G.
Publicado: (2018)

Sub-differentiation of PI-RADS 3 lesions in TZ by advanced diffusion-weighted imaging to aid the biopsy decision process
por: Zhou, Kun-Peng, et al.
Publicado: (2023)

Reducing the number of unnecessary biopsies for mammographic BI-RADS 4 lesions through a deep transfer learning method
por: Meng, Mingzhu, et al.
Publicado: (2023)

TRUS-Guided Target Biopsy for a PI-RADS 3–5 Index Lesion to Reduce Gleason Score Underestimation: A Propensity Score Matching Analysis
por: Chung, Jae Hoon, et al.
Publicado: (2022)

Structured reporting in radiologic education – Potential of different PI-RADS versions in prostate MRI controlled by in-bore MR-guided biopsies
por: Garmer, Marietta, et al.
Publicado: (2022)

Prostate Cancer Detection with mpMRI According to PI-RADS v2 Compared with Systematic MRI/TRUS-Fusion Biopsy: A Prospective Study
por: Sauck, Anja, et al.
Publicado: (2022)

Correlation between Intraprostatic PSMA Uptake and MRI PI-RADS of [(68)Ga]Ga-PSMA-11 PET/MRI in Patients with Prostate Cancer: Comparison of PI-RADS Version 2.0 and PI-RADS Version 2.1
por: Zhao, Jing, et al.
Publicado: (2020)

Multiparametric MRI for Prostate Cancer Characterization: Combined Use of Radiomics Model with PI-RADS and Clinical Parameters
por: Woźnicki, Piotr, et al.
Publicado: (2020)

Standards for MRI reporting—the evolution to PI-RADS v 2.0
por: Spektor, Michael, et al.
Publicado: (2017)

Results from a PI-RADS-based MRI-directed diagnostic pathway for biopsy-naive patients in a non-university hospital
por: Reijnen, Jeroen S., et al.
Publicado: (2021)

Combination of ultrafast dynamic contrast-enhanced MRI-based radiomics and artificial neural network in assessing BI-RADS 4 breast lesions: Potential to avoid unnecessary biopsies
por: Lyu, Yidong, et al.
Publicado: (2023)

Prediction of significant prostate cancer in biopsy-naïve men: Validation of a novel risk model combining MRI and clinical parameters and comparison to an ERSPC risk calculator and PI-RADS
por: Radtke, Jan Philipp, et al.
Publicado: (2019)

Primary follicular lymphoma of the prostate presenting with elevated PSA and a PI-RADS 3 lesion on MRI: A case report
por: Jia, Hanna, et al.
Publicado: (2022)

Development and validation of a nomogram based on biparametric MRI PI-RADS v2.1 and clinical parameters to avoid unnecessary prostate biopsies
por: Wang, Yunhan, et al.
Publicado: (2023)

Prostate MRI based on PI-RADS version 2: how we review and report
por: Steiger, Philipp, et al.
Publicado: (2016)

Autonomous Detection and Classification of PI-RADS Lesions in an MRI Screening Population Incorporating Multicenter-Labeled Deep Learning and Biparametric Imaging: Proof of Concept
por: Winkel, David J., et al.
Publicado: (2020)

Reduction of MRI-targeted biopsies in men with low-risk prostate cancer on active surveillance by stratifying to PI-RADS and PSA-density, with different thresholds for significant disease
por: Schoots, Ivo G., et al.
Publicado: (2018)

Multiparameter MRI Model With DCE-MRI, DWI, and Synthetic MRI Improves the Diagnostic Performance of BI-RADS 4 Lesions
por: Sun, Shi Yun, et al.
Publicado: (2021)

Validation of the PI-RADS language: predictive values of PI-RADS lexicon descriptors for detection of prostate cancer
por: Rudolph, Madhuri M., et al.
Publicado: (2020)

Utility of Clinical–Radiomic Model to Identify Clinically Significant Prostate Cancer in Biparametric MRI PI-RADS V2.1 Category 3 Lesions
por: Jin, Pengfei, et al.
Publicado: (2022)

Automated Breast Volume Scanner (ABVS)-Based Radiomic Nomogram: A Potential Tool for Reducing Unnecessary Biopsies of BI-RADS 4 Lesions
por: Wang, Shi-Jie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jimnql4ncsgg9vn1aun3qa77ub